Raymond James lowered the firm’s price target on Pacira to $37 from $41 and keeps an Outperform rating on the shares. Pacira reported solid Q2 results, but the focus remains on the judge’s decision for the first Exparel patent case expected by August 1, the analyst tells investors in a research note. Regardless of the outcome, Pacira feels there is a very long road ahead with numerous patents for the recently approved generic still to navigate around, the firm notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira (PCRX) Q2 Earnings Cheat Sheet
- Pacira negative patent ruling most likely outcome, says JPMorgan
- CMS proposes new reimbursement for Exparel in outpatient surgical enviroments
- Centers for Medicare and Medicaid Propose New Reimbursement for EXPAREL in All Outpatient Surgical Environments Beginning January 1, 2025
- Intuit initiated, Charter downgraded: Wall Street’s top analyst calls